None
Quote | Genmab A/S (NYSE:GMAB)
Last: | $ |
---|---|
Change Percent: | -2.01% |
Open: | $24.00 |
Close: | $23.84 |
High: | $24.01 |
Low: | $23.83 |
Volume: | 215,311 |
Last Trade Date Time: | 02/12/2020 04:43:03 pm |
News | Genmab A/S (NYSE:GMAB)
2024-04-16 11:20:38 ET Summary Genmab will acquire ProfoundBio for $1.8 billion in cash. The acquisition adds an important antibody drug conjugate ('ADC') platform, a missing piece in Genmab's platform. Genmab plans to advance ProfoundBio's lead candidate, Rina-S, to registrat...
2024-04-16 07:20:23 ET Reporting its Q1 2024 results, Big Pharma’s earnings bellwether, Johnson & Johnson ( NYSE: JNJ ), revised its full-year outlook below consensus on Tuesday after sales from its MedTech division fell short of Street forecasts.... Read the full a...
Message Board Posts | Genmab A/S (NYSE:GMAB)
Subject | By | Source | When |
---|---|---|---|
Emylers: GMXAY Financials 07/16/2014 18:58:03 Genmab A/S Period Ending Total Revenue Cost of Revenue | Emylers | investorshangout | 07/16/2014 11:57:58 PM |
chartguy89: GMXAY 22.23 Stock Charts $GMXAY 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 5:48:58 PM |
chartguy89: GMXAY Stock Charts Last: -0.44 Wednesday, February 26, 2014 at 12:53:33 PM $GMXAY | chartguy89 | investorshangout | 02/26/2014 5:53:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Company Name:
GMAB Stock Symbol:
NYSE Market:
2024-04-02 01:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-23 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
FDA grants Priority Review with target action date of June 28, 2024 Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in difficult-to-treat patients with relapsed or refractory (R/R) follicular lymphoma (FL) ...